2016
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5
Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016, 7: 30585-30596. PMID: 27105526, PMCID: PMC5058703, DOI: 10.18632/oncotarget.8874.Peer-Reviewed Original ResearchConceptsComplement C5Liver metastasesAdvanced tumorsNeuroendocrine tumorsMouse modelSmall primary tumorsPancreatic neuroendocrine tumorsTypes of tumorsSmall molecule antagonistsIntratumoral levelsPrimary tumorMale miceComplement C5aMetastasisTumorsMolecule antagonistsMiceHigh frequencySexual dimorphismHuman diseasesMalesFirst reportCD88CD68PMX53
2010
A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum
Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, DeWan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocrine Related Cancer 2010, 18: 171-180. PMID: 21139019, PMCID: PMC3221459, DOI: 10.1677/erc-10-0248.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCell DifferentiationCellsDNA Copy Number VariationsFemaleGenetic VariationGenome-Wide Association StudyHumansIleal NeoplasmsMaleMeta-Analysis as TopicMicroarray AnalysisNeoplasm StagingNeuroendocrine TumorsPilot ProjectsPolymorphism, Single NucleotideReview Literature as TopicConceptsLoss of heterozygosityDana-Farber Cancer InstituteTumor cellsMD Anderson Cancer CenterCarcinoid tumor cellsUppsala University HospitalPopulation-based controlsAnderson Cancer CenterCopy number variantsBonferroni-corrected levelBlood-derived DNACarcinoid cancerReal-time quantitative PCRCancer CenterNeuroendocrine tumorsUniversity HospitalNon-tumor cellsSerious conditionIndependent cohortCancer InstituteKb heterozygous deletionSmall sample sizePilot genome-wide association studyGenetic polymorphismsSingle nucleotide polymorphisms
2001
Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis
Akpek G, Lenz G, Lee S, Sanchorawala V, Wright D, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo R. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation 2001, 28: 1105-1109. PMID: 11803350, DOI: 10.1038/sj.bmt.1703298.Peer-Reviewed Original ResearchConceptsStem cell transplantationAutologous blood stem cell transplantationBlood stem cell transplantationAbsolute lymphocyteT cellsImmunoglobulin levelsCell transplantationAL amyloidosisProliferative responsePost-stem cell transplantationT cell proliferative responsesNumber of CD4Post-transplant immunosuppressionCellular immune functionSerum immunoglobulin levelsT-cell immunosuppressionCell proliferative responsesT cell proliferationB cell functionInitial study groupImmunologic recoveryLymphoid recoveryPCP pneumoniaCell immunosuppressionLymphocyte subsets
2000
Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
Scharrer I, Brackmann H, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000, 6: 614-618. PMID: 11122384, DOI: 10.1046/j.1365-2516.2000.00432.x.Peer-Reviewed Original Research
1999
Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis
COMENZO R, SANCHORAWALA V, FISHER C, AKPEK G, FARHAT M, CERDA S, BERK J, DEMBER L, FALK R, FINN K, SKINNER M, VOSBURGH E. Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Of Haematology 1999, 104: 553-559. PMID: 10086794, DOI: 10.1046/j.1365-2141.1999.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyloidosisAntineoplastic Agents, AlkylatingDrug CombinationsFemaleGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousLeukapheresisMaleMelphalanMiddle AgedSurvival AnalysisConceptsBlood stem cellsMobilization regimensG-CSFIntermediate dose (15-30 mg/m2, day 1) intravenous melphalanDose-intensive melphalanPhase 11 trialGrade 4 toxicityComplete haematological responseCells/AL amyloidosis patientsTerms of CD34Stem cellsActive regimenMobilization patientsDose melphalanOrgan involvementIntravenous melphalanCardiac amyloidD mortalityMonths 57AL amyloidosisAmyloidosis patientsHaematological responsePatientsDay 5
1998
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. PMID: 9573002, DOI: 10.1182/blood.v91.10.3662.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisAntineoplastic Agents, AlkylatingCohort StudiesCombined Modality TherapyErythrocyte TransfusionFemaleHematopoietic Stem Cell TransplantationHumansKidneyLife TablesLiverMaleMelphalanMiddle AgedMyocardiumNervous SystemParaproteinsPlatelet TransfusionPrognosisRecurrenceSeverity of Illness IndexSurvival AnalysisTransplantation ConditioningTreatment OutcomeConceptsClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapy
1996
Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients
Comenzo R, Vosburgh E, Simms R, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D, Wright D, Falk R, Skinner M. Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients. Blood 1996, 88: 2801-2806. PMID: 8839879, DOI: 10.1182/blood.v88.7.2801.bloodjournal8872801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisCardiomyopathiesFeasibility StudiesFemaleFollow-Up StudiesGastrointestinal DiseasesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHepatomegalyHumansKarnofsky Performance StatusMaleMelphalanMiddle AgedNephrotic SyndromeNeutropeniaPeripheral Nervous System DiseasesPrednisoneRemission InductionTreatment OutcomeConceptsBlood stem cell supportStem cell supportPlasma cell dyscrasiaDose-intensive melphalanPerformance statusAL amyloidosisCell dyscrasiaCell supportClinical remissionIntravenous melphalanBone marrow biopsy specimensDose-intensive chemotherapyFibrillar amyloid proteinsImproved performance statusMedian performance statusSurvival of patientsTime of diagnosisReversal of symptomsBlood stem cellsClonal plasma cellsOne-year followOrgan-specific diseasesMarrow biopsy specimensForm of treatmentDaily proteinuriaTiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright D, Boosalis M, Waraska K, Oshry L, Weintraub L, Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Research 1996, 16: 3349-51. PMID: 9042310.Peer-Reviewed Original ResearchConceptsLeukemic blastsBlast crisisMRNA expressionCML-BC patientsPhase II trialBlood of patientsCycle-active agentsChronic myelogenous leukemiaDays of treatmentCML blast crisisHematologic remissionII trialTrial patientsHematologic responseTiazofurin treatmentWBC countIMP dehydrogenase activityCML-BCPartial clearanceMyelogenous leukemiaLeukemic clonePatientsNeoplastic cellsSequential coursesProliferative activity
1995
Collection of mobilized blood progenitor cells for hematopoietic rescue by large‐volume leukapheresis
Comenzo R, Vosburgh E, Weintraub L, Tansan S, Arkin C, Wright D. Collection of mobilized blood progenitor cells for hematopoietic rescue by large‐volume leukapheresis. Transfusion 1995, 35: 493-497. PMID: 7770900, DOI: 10.1046/j.1537-2995.1995.35695288768.x.Peer-Reviewed Original ResearchConceptsBlood progenitor cellsDose-intensive chemotherapyRapid hematopoietic reconstitutionMononuclear cellsLarge-volume leukapheresisClonogenic progenitor cellsLVL proceduresProgenitor cellsHematopoietic rescueHematopoietic reconstitutionColony-stimulating factor administrationCFU-GMAutologous hematopoietic rescuePercent of patientsHigh-dose chemotherapyProgenitor cell collectionColony-stimulating factorLimited chemotherapyPatient weightCancer patientsFactor administrationPlatelet recoveryTarget dosesChemotherapyPatients
1992
Pruritus secondary to hydroxyurea therapy in a woman with polycythemia vera
Vosburgh E. Pruritus secondary to hydroxyurea therapy in a woman with polycythemia vera. American Journal Of Hematology 1992, 41: 70-70. PMID: 1503109, DOI: 10.1002/ajh.2830410120.Commentaries, Editorials and Letters